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VirotherapyAdenoviruses with deletion of E1b have been used in clinical trials to treat cancers that are resistant to
conventional therapies. The efﬁcacy of viral replication within cancer cells determines the results of oncolytic
therapy, which remains poorly understood and requires further improvement. In this report, we show that
adenoviruses induce autophagy by increasing the conversion of LC3-I to LC3-II and the formation of the
Atg12–Atg5 complex. Inhibition of autophagy with 3-methyladenine (3MA) resulted in a decreased synthesis
of adenovirus structural proteins, and thereby a poor viral replication; promotion of autophagy with
rapamycin increased adenovirus yield. This study indicates that adenovirus-induced autophagy correlates
positively with virus replication and oncolytic cell death, and that autophagy may generate nutrients that can
be used for building viral progeny particles. These results further suggest that chemotherapeutic agents that
increase cancer cell autophagy may improve the efﬁcacy of oncolytic virotherapy.Cancer Center, University of
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Adenoviruses (Ads) with E1b deletion can selectively replicate in
cancer cells and cause oncolysis. Oncolytic viruses have been used in
clinical trials and cancer treatments (Crompton and Kirn, 2007;
Garber, 2006; Koski et al., 2010); however, as single agents, the
antitumoral effects of oncolytic Ads have been somewhat disappoint-
ing in preclinical and clinical trials (Kirn et al., 2001; McCormick,
2003; Yamamoto and Curiel, 2010; Zhao et al., 2003). We previously
reported that intratumoral injection of viruses could efﬁciently inhibit
small human tumor growth in an animal model, but could not
efﬁciently repress large tumors (Zhao et al., 2003). Many clinical
studies have shown that the oncolytic approach alone could not
efﬁciently destroy tumors in patients, especially for large tumors (Kirn
et al., 2001; McCormick, 2003). Thus, oncolytic virus replication and
spread are likely restricted in the larger tumor mass. This restriction
may be a major hurdle limiting the efﬁcacy of virotherapy. We believe
that increasing the efﬁcacy of viral replication within cancer cells will
improve the results of oncolytic therapy.
Autophagy is a regulated process of degradation and recycling of
cellular constituents, this process is important in organelle turnover
and the bioenergetics management of starvation (Levine andKlionsky, 2004; Ohsumi, 2001). Autophagy starts with formation of
double-membrane vesicles containing cytoplasm and organelles, a
structure known as autophagosome. Ultimately, autophagosomes
fuse with lysosomes where the bulk cytoplasmic content undergoes
degradation, resulting in the liberation of amino acids and fatty acids
that can be reused by cells (Baehrecke, 2005; Klionsky, 2008; Klionsky
and Emr, 2000). During autophagy, several autophagy (Atg) proteins
have been implicated in autophagosome formation. Atg5 and Atg12
form a complex that is required to recruit other proteins to the
autophagosomal membrane. LC3 is the mammalian equivalent of
yeast Atg8. The precursor form of LC3 is post-modiﬁed into two forms,
LC3-I and LC3-II. LC3-I is localized in the cytosol and LC3-II in
autophagosomal membranes. LC3-II can be used to estimate the
abundance of autophagosomes before they are destroyed through
fusion with lysosomes. Thus, Atg5/Atg12 complex formation, and the
LC3-II conversion and integration into autophagosomal membrane,
are the major hallmarks of activation of the autophagic process.
Some reports have suggested that autophagy has dual roles, acting
as a survival mechanism and as a caspase-independent form of
programmed cell death (Gozuacik and Kimchi, 2007; Wang et al.,
2006; Yu et al., 2004). Autophagy is also involved in combating
infection by breaking down pathogens (Gutierrez et al., 2004).
However, some viruses subvert the autophagic pathway to promote
their own replication (Jackson et al., 2005). The role of autophagy in
Ad-mediated oncolytic cell death has not been well characterized.
Kondo's group has reported that hTERT-Ad, a conditionally replicating
Ad regulated by the human telomerase reverse transcriptase
promoter, killed cancer cells by inducing autophagy instead of
apoptosis, and proposed that autophagy is an antitumoral effect, not
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Their study was supported by a report showing that brain tumor cells
were susceptible to Ad-mediated cell death via autophagy in vitro and
in vivo (Jiang et al., 2007). In contrast, Baird et al.(2008) have reported
that autophagy acts as a cell survival response to Ad infection in
ovarian cancer, as an inhibitor of autophagy decreased cell survival.
Thus, the autophagic functions in viral oncolytic replication need
further investigation.
In this report, we have applied wild-type (wt) Ad5, Adhz60 (with
deletion of E1b) (Rao et al., 2004), and AdlacZ (with deletion of both
E1a and E1b, and replication defective) to study Ad-induced
autophagy. We observed that Ad5 and Adhz60 can induce autophagy,
but AdlacZ cannot. Ad5 and Adhz60 promote the conversion of LC3-I
to LC3-II and formation of the Atg12–Atg5 complex. However, these
processes were more pronounced in cells infected with Ad5, which
expresses both E1a and E1b, suggesting that the E1b gene deleted in
Adhz60 is not essential for autophagy but enhances it. We show that
inhibition of autophagy decreases viral protein production and virus-
induced autophagy correlates positively with virus replication. Our
results suggest that chemotherapeutic agents that increase cancer
autophagy may improve the efﬁcacy of Ad-mediated oncolysis.
Results
Adenoviruses induce autophagy activation
To study Ad-triggered autophagy in lung cancer cells, we ﬁrst
applied the Gaussia luciferase (GLUC)-based assays to monitor the
autophagic signaling pathway (Ketteler and Seed, 2008). This
autophagy assay speciﬁcally measures the proteolytic cleavage of
LC3 by the autophagy-activated protease Atg4B. In this system, the
LC3 gene is linked with β-actin and GLUC genes to form the tripartite
Actin-LC3-GLUC in the plasmid pEAK12-Actin-LC3-dNGLUC (Ketteler
and Seed, 2008). During autophagy, activation of Atg4B cleaves at LC3
in the tripartite sensor protein Actin-LC3-GLUC and releases GLUC,
which is secreted to the culture medium. The levels of released GLUC
indicate the degree of autophagy activation (Ketteler and Seed, 2008).
In our experiment, A549 lung cancer cells were transfected with
pEAK12-Actin-LC3-dNGLUC following infection with Ad5 (wt) or
Adhz60 (deleted-E1b) at a multiplicity of infection (MOI) value of 4 or
AdlacZ (deleted-E1a and E1b) at an MOI of 10. We used a higher MOI
for AdlacZ to compensate for the fact that this virus does not replicate.
We observed that both Ad5 and Adhz60 increased GLUC activity in a
time-dependent manner, and Ad5 induced signiﬁcantly higher GLUC
activity in comparison with that of Adhz60. At 36 h post-infection,
Ad5 increased the Relative Luminescence Units (RLU) to 230,000, but
Adhz60 increased to only 80,000 RLUs. The GLUC activity levels from
AdlacZ-infected cells were similar to that of mock treatment (Fig. 1).Fig. 1. Quantiﬁcation of autophagy activation. A549 cells were transfected with
pEAK12-Actin-LC3-dNGLUC followed by no infection (mock) or infection with Ad5,
Adhz60 (MOI=4), or AdlacZ (MOI=10). AdlacZ with deletion of E1 gene is used as a
negative control vector incapable of replication. Secretion of LC3/GLUC was monitored
over the time with the Renilla Luciferase kit (Promega). Each point represents the mean
of three independent experiments±standard deviation (SD; bars).Similar results were obtained when AdlacZ was used at either at an
MOI value of 4 or 20 (data not shown). These results were important
in that both Ad5 and Adhz60 were able to trigger the activation of the
autophagic pathway, and that the E1b gene (deleted in Adhz60) may
be involved in enhancing this activity.
Adenoviruses induce autophagosome formation in lung cancer cells
One hallmark of autophagy activation is the formation of cellular
autophagosome puncta containing LC3-II. LC3-II is the only known
mammalian protein that stably binds to the autophagosomal
membrane after the cytoplasmic form LC3-I is converted to LC3-II
by site-speciﬁc proteolysis during autophagy. To investigate LC3-II
incorporation into autophagosome, we used the GFP-tagged LC3
plasmid, pEGFP-LC3 (Kabeya et al., 2000). A549 lung cancer cells were
transfected with pEGFP-LC3, and then infected with Ads as described
earlier. Conversion of cytoplasm-diffuse GFP to membrane-associated
GFP puncta was observed at 36 h by ﬂuorescence microscopy
(Fig. 2A), indicating that there was GFP-LC3-II incorporation into
the autophagosomes. Ad5 and Adhz60 induced a signiﬁcant number
of cells with the GFP punctual pattern. The percentage of cells with the
GFP punctuate pattern was calculated as punctuate GFP cell per total
GFP cell percentage (Fig. 2B). Ad5 induced a higher percentage of cells
(76%) with the GFP punctual pattern than Adhz60 (58%). In contrast,
cells infected with AdlacZ exhibited a diffuse cytoplasmic pattern or
low percentage (6%) of cells with this punctual pattern.
Ad E1a and E1b activate LC3 conversion and Atg12–Atg5 complex
formation
In the aforementioned experiments, we found that Ad5 induced
higher autophagy activation and more autophagosome formation
than Adhz60. At the protein level, we investigated whether E1b
deletion in Adhz60may result in a less efﬁcient conversion of LC3-1 to
LC3-II and the formation of the Atg12–Atg5 complex, which are other
hallmarks of autophagy. To study this, A549 cells were infected with
Ads, and cellular proteins were collected at 0-, 24-, 48-, and 72-h post-
infection. An immunoblotting assay revealed the two active species of
LC3, the upper band corresponding to LC3-I and lower band
corresponding to LC3-II (Kabeya et al., 2000). Signiﬁcant conversion
of LC3-I to LC3-II was readily detected after Ad5 infection; nearly all
LC3-I was converted to LC3-II after 48 h post-infection (Fig. 3). There
was partial conversion from LC3-I to II in cells infected with Adhz60.
For AdlacZ-treated cells, there was no detectable change of relative
amounts of LC3-I and LC3-II. The apparent molecular weight of the
LC3-I and LC3-II proteins are different to the all known values of
adenoviral proteins.
We next analyzed Atg5 expression and its conjugation with Atg12.
Conjugation of Atg5 with Atg12 is essential in the early stage of
autophagy for the elongation of the isolation membrane during
autophagosome formation (Mizushima et al., 2001). We observed
that Ad5 induced a considerable increase of Atg12–Atg5 complex after
infection (Fig. 3). Infection with Adhz60 also caused the formation of
the Atg12–Atg5 complex, but at lower levels compared with Ad5.
There was no change of these proteins and complexes in AdlacZ-
infected cells (Fig. 3). These data suggest that the lack of E1b resulted
in a less efﬁcient conversion of LC3-1 to LC3-II and formation of the
Atg12–Atg5 complex.
Pharmacological inhibition of autophagy decreases the yield of
adenoviruses
Autophagy may be an intracellular host defensive mechanism
against viruses, or it can be used by viruses for their own beneﬁt of
efﬁcient replication (Colombo, 2005). We examined the effect of
autophagy on Ad replication. Since 3MA inhibits autophagy by
Fig. 2. Autophagy activation and integration of LC3 into autophagosome. A549 cells were transfected with pEGFP-LC3 followed by infection with Ad5, Adhz60, or AdlacZ.
(A) Integration of GFP-LC3 into the autophagosome is depicted by punctate structures (indicated by arrows) and was analyzed by ﬂuorescence microscopy at 36 h p.i. Images were
taken with Kodak MDS 290 software (magniﬁcation ×40). (B) The percentage of cells with punctate GFP-LC3 ﬂuorescence was calculated relative to all GFP-LC3-positive cells. A
representative experiment is shown from three performed.
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(Kondo et al., 2005; Shintani and Klionsky, 2004), A549 cells were
infected with Ad5 or Adhz60 in the absence or presence of 3MA at a
concentration of 10 mM. Viruses were harvested after infection and
titered on HEK-293 cells. We observed that the autophagy inhibitor
3MA reduced the viral yields about 10-fold for both Ad5 and Adhz60
(Fig. 4A). The differences were statistically signiﬁcant, as shown by
the Student t-test.
It is well known that autophagy degrades intracellular compo-
nents, such as organelles and long-lived proteins, to liberate amino
acids and fatty acids that can be reused within cells, especially underFig. 3. Expression of the classical autophagy hallmarks. A549 cells were infected with Ad5, A
course assay. LC3-I and LC3-II were detected with a pAb anti-LC3. To detect Atg5 or Atg12–starvation condition (Baehrecke, 2005; Klionsky, 2008; Klionsky and
Emr, 2000). Therefore, it is possible that Ads may promote autophagy
to provide elements for viral particle production. If so, inhibition of
autophagy should decrease or delay viral protein synthesis. We
analyzed the production of viral structure proteins in cells treated
with the autophagy inhibitor 3MA. The production of viral structural
proteins of both Ad5 and Adhz60 at 24 h was strongly inhibited in
cells treated with 3MA (Fig. 4B). The decreased viral protein
production, caused by 3MA treatment, correlates with inefﬁcient
virus replication as shown in Fig. 4A. These results suggest that
autophagy plays a critical role in viral structure protein synthesis,dhz60, or AdLacZ. LC3 and Atg5 expression and modiﬁcation were analyzed in a time-
Atg5 complex, a pAb anti-Atg5 was used.
Fig. 4. Effect of 3-methyladenine (3MA) on adenovirus yield and structural protein
production. A549 cells were infected with Ad5 or Adhz60 in absence or presence of
3MA. Cells were harvested at indicated time points. (A) For titering, supernatants were
serially diluted to determine the titers, plaque forming unit (PFU), in HEK-293 cells.
Each point represents the mean of three independent experiments±standard
deviation (SD; bars; Pb0.05). (B) Ad structural proteins were detected with rabbit-
antihuman Ad protein virions. One experiment is shown from three performed.
Fig. 5. Inhibition or induction of autophagosome formation and inhibition of LC3-I to
LC3-II conversion. (A) A549 cells were transfected with pEGFP-LC3 following infection
with Ad5 (MOI=4) in absence or presence of 3MA (10 mM). (B) A549 cells were
transfected with pEGFP-LC3 followed by no treatment or treatment with rapamycin
(50 nM). Integration of GFP-LC3 into the autophagosome is depicted by punctate
structures (indicated by arrows) and was analyzed by ﬂuorescence microscopy at 36 h
p.i. Images were taken with Kodak MDS 290 software (magniﬁcation, ×40). (C) A549
cells were infected with Ad5 in presence of 3MA (10 mM). LC3 expression was analyzed
in a time-course assay. LC3-I and LC3-II were detected with a pAb anti-LC3. A
representative experiment is shown from three performed.
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progeny virus particles.
Treatment of Ad5-infected cells with 3MA prevents autophagosome
formation and inhibits the conversion of LC3-I to LC3-II
We investigated whether 3MA could prevent the conversion of
GFP-LC3-1 to GFP-LC3-II induced by Ad5. A549 cells were transfected
with pEGFP-LC3 followed by infection with Ad5. The treated cells
were then cultured in the absence or presence of 3MA at a
concentration of 10 mM. We found that 3MA repressed the conver-
sion of LC3-I to LC3-II, resulting in a diffuse GFP-LC3 pattern (Fig. 5A).
We further investigated whether 3MA might inhibit conversion of
LC3-I to LC3-II at the protein level. We analyzed the effect of 3MA in
cells infected with Ad5, because this virus induced signiﬁcant
conversion of LC3-I to LC3-II. A549 cells were infected with Ad5 in
the presence of 3MA (Fig. 5C). The conversion of LC3-I to LC3-II was
signiﬁcantly inhibited by 3MA in Ad5-infected cells compared to the
result in the absence of 3MA (Fig. 3). The results indicate that
inhibition of autophagy with 3MA results in decreased viral
replication.
Role of autophagy in adenovirus replication and oncolysis
To further investigate the role of autophagy in oncolytic therapy,
we compared the effect of 3MA (autophagy inhibitor) and rapamycin
(autophagy inducer) on virus replication and cancer cell viability.
First, we veriﬁed the autophagy induction function of rapamycin in
our experimental conditions. Rapamycin induces autophagy by
inhibiting the mammalian target of rapamycin (mTOR), an autop-
hagy-associated molecule (Kondo et al., 2005; Shintani and Klionsky,
2004). A549 cells were transfected with pEGFP-LC3 followed by
treatment with rapamycin at a concentration of 50 nM. Conversion ofthe cytoplasm-diffused pEGFP-LC3-I to membrane-associated pEGFP-
LC3-II puncta was observed by ﬂuorescence microscopy at 36 h
(Fig. 5B), indicating that rapamycin indeed induced autophagy in
A549 cells.
A549 cells were infected in the presence or absence of 3MA or
rapamycin. The virus progeny produced in A549 cells were deter-
mined at day 3 after infection. In the presence of 3MA, there was
signiﬁcant inhibition of Ad5 and Adhz60 yields: 30- and 10-fold
decrease, respectively (Fig. 6A). We also observed that rapamycin
treatment increased the virus titers of Ad5 and Adhz60 2- to 3-fold
higher than that of untreated cells (Fig. 6A). The results, as well as the
results shown in Figs. 4 and 5, suggest that autophagy has a positive
effect on Ad replication.
Next, MTT assay was used to determine the relative cell survival.
This assay showed that cells infected with Ad5 or Adhz60 at an MOI of
4 resulted in 28% and 63% viability at 72 h, respectively. Treatment
with 3MA prevented cell death and increased the cell viability to 48%
for Ad5 and 85% for Adhz60 (Fig. 6B). Unlike 3MA, rapamycin did not
signiﬁcantly affect the cell survival rate (Fig. 6C). Thus, inhibition of
autophagy signiﬁcantly reduces virus replication and decreases the
oncolytic effect.
Oncolytic adenovirus induces activation of autophagy in different types
of cancer cells
Since the ability of oncolytic Ads to induce autophagy in A549 lung
cancer cells was demonstrated, we studied whether these Ads could
Fig. 6. Effect of pharmacological inhibition and stimulation of autophagy on adenovirus
replication and oncolysis. (A) A549 cells were infected with Ad5 or Adhz60 in the
presence or absence of 3MA (10 mM) or rapamycin (50 nM). Seventy-two hours later,
titers were determined by serial dilutions of supernatants and titers were measured by
standard infection units. Cytotoxicity was analyzed by a MTT assay at 72 h after 3MA
(B) or rapamycin (C) treatment. Each point represents the mean of three independent
experiments±(SD; bars).
Fig. 7. Activation of autophagy in different types of cancer cells. Hela, HCT116, RKO, or
H1299 cancer cell lines were transfected with pEAK12-Actin-LC3-dNGLUC followed by
no infection (mock) or infection with Ad5 or Adhz60 (MOI=4). Secretion of LC3/GLUC
was monitored at 36 h after infection with the Renilla Luciferase kit (Promega). Each
point represents themean of three independent experiments±standard deviation (SD;
bars).
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Therefore, Hela cervical cancer cells, HCT116, and RKO colon cancer
cells, or H1299 lung cancer cells were transfected with pEAK12-Actin-
LC3-dNGLUC followed by no infection (mock) or infection with Ad5
(wt) or Adhz60 (deleted-E1b) at an MOI of 4. GLUC activity was
measured 36 h after infection; mock level was used as a baseline. It
was observed that both Ad5 and Adhz60 induced activation of
autophagy in Hela, RKO, and H1299 cells; H1299 showed the highest
autophagy activation (Fig. 7). Ad5 also induced autophagy activation
in HTC116 cells. Even though our experiment did not attempt to
address optimal conditions for induction of autophagy by virus
infection for each of the cell lines, the results indicate that Ads can
generally induce autophagy in cancer cells.Discussion
Ads have been genetically modiﬁed for selectively replicating
within cancer cells and causing oncolysis. The advantage of virother-
apy is that the released progeny viruses further spread infection until
all cancer cells are destroyed. This is true for cancer cells in tissue
culture. Even when less than 1 percent of the cancer cells are initially
infected, all cancer cells are eventually killed in a few days. However,
animal experiments and clinical trials have indicated that virus
replication and spread in larger tumor masses are restricted, and that
the restricted replication and spread may be major hurdles limiting
the efﬁcacy of virotherapy (Kirn, 2001; McCormick, 2003; Yamamoto
and Curiel, 2010; Zhao et al., 2003). Recent studies suggest that Ads
have the ability to induce autophagy (Baird et al., 2008; Ito et al.,
2006; Jiang et al., 2007, 2008). Thus, autophagy may be used to
promote virus replication and improve oncolysis.
In this study, we have applied wild-type (wt) Ad5, Adhz60 (with
deletion of E1b) (Rao et al., 2004), and AdlacZ (with deletion of both
E1a and E1b) to study Ad-induced autophagy. We observed that
autophagy is induced by replication-competent Ad5 and Adhz60, but
not by AdlacZ. We also found that Ad5 and Adhz60 promote the
conversion of LC3-I to LC3-II and the formation of the Atg12–Atg5
complex—two hallmarks of autophagy. These processes were more
pronounced in cells infected with Ad5, which expresses both E1a and
E1b, than in cells infected with the E1b-deleted Adhz60. Thus,
autophagy induction appears to be dependent on the E1a gene and
viral replication, and the E1b gene may be involved in enhancing
autophagy. We do not know the exact mechanisms by which Ad
infection activates autophagy. Ad infection may initially trigger
cellular autophagic responses that can be taken over by Ads for the
beneﬁt of viral replication. It is also possible that a virus-associated or
activated protease activity may directly contribute to the conversion
of LC3-I to LC3-II and activate the autophagy pathway.
To study the role of autophagy in Ad replication, we have applied
3MA to inhibit autophagy and rapamycin to promote the process.
Both 3MA and rapamycin have been broadly used in autophagy
studies (Kondo et al., 2005; Shintani and Klionsky, 2004). It is known
that 3MA inhibits autophagy by suppressing the formation of the pre-
autophagosomal structure. Rapamycin inhibits the mammalian target
of rapamycin (mTOR), an autophagy-associated molecule, and is used
in model studies to induce autophagy. Although we cannot exclude
the possibility that 3MA and rapamycin may also affect other
processes in the Ad-infected cells, we have shown that 3MA partially
represses Ad-induced autophagy, and rapamycin alone can induce
autophagy in treated cancer cells in our experimental set (Fig. 5). We
observed that 3MA signiﬁcantly reduced Ad5 and Adhz60 yields in
14 H. Rodriguez-Rocha et al. / Virology 416 (2011) 9–15A549 cancer cells and partially prevented Ad-caused cell death
(Fig. 6A and B). Rapamycin increased Ad5 and Adhz60 titers 2- to 3-
fold (Fig. 6A). Since Ad oncolytic replication is restricted in large
tumor masses, promotion of autophagy with chemotherapeutic
agents may have the potential to improve the efﬁcacy of virotherapy.
To the best of our knowledge, this study shows, for the ﬁrst time,
that 3MA represses Ad structure protein synthesis (Fig. 4). Autophagy
is a catabolic process involving the degradation of cellular compo-
nents through the lysosomal machinery. Autophagy is a major
mechanism by which a starving cell reallocates nutrients from
unnecessary processes to more-essential processes, although this
process also plays a number of other roles in normal cell growth,
development, and homeostasis (Levine and Klionsky, 2004; Ohsumi,
2001). We have shown that replication-competent Ads strongly
induce autophagy in cancer cells; inhibition of autophagy with 3MA
partially represses viral protein production and decreases virus titers,
and the autophagy inducer, rapamycin, increases virus replication.
These results have indicated that virus-induced autophagy correlates
positively with virus replication. Since autophagy has amajor function
in the generation of nutrients for starving cells, and inhibition of
autophagy speciﬁcally represses viral structural protein synthesis
(Fig. 4), we hypothesize that autophagymay play a critical role in viral
replication by degrading intracellular components for building
progeny virus particles.
We also observed that replicative Ads can activate autophagy in
other cancer cell lines, Hela, HCT116, RKO, and H1299, but the levels
are different from cell to cell. This may reﬂect the different
sensitivities of cancer cells to Ad-induced autophagy or that optimal
conditions are not selected for each of the cell lines, such as
transfection efﬁcacy of plasmid and autophagy peaking time points.
A new publication has shown that human adenovirus type 5 induces
autophagy in glioma cells (Jiang et al., 2011). Thus, it is likely that
oncolytic Ads are generally able to induce the activation of autophagy.
In summary, we found that wt Ad5 and E1b-deleted oncolytic
Adhz60 induced autophagy in cancer cells, the conversion of LC3-I to
LC3-II and the complex formation of Atg12–Atg5. Autophagy
correlated positively with virus replication and oncolytic cell death.
Based on these ﬁndings, we suggest that chemotherapeutic agents
that increase cancer cell autophagy may promote the efﬁcacy of
oncolytic virotherapy. These ﬁndings may have clinical relevance in
the development of oncolytic virotherapy.
Material and methods
Cell line and culture conditions
Human lung cancer cell lines A549 and H1299 were cultured in
MEM-Alphamedium; human cervical cancer cell line Hela and human
colon cancer cell line RKOwere cultured in RPMImedium; and human
colon cancer cell line HCT116 was cultured in McCoy's medium at
37 °C in a humid incubatorwith 5% CO2. All media were supplemented
with 10% heat-inactivated fetal bovine serum (FBS) and penicillin/
streptomycin (100 U/ml). All cell culture reagents were obtained from
Gibco BRL (Bethesda, MD). Adherent cells were collected after trypsin
treatment, and cell numbers were determined using a Neubauer cell
counting chamber. All experimentswere repeated at least three times.
Plasmids
The pEAK12-Actin-LC3-dNGLUC (autophagy sensor) was kindly
provided by Dr. Brian Seed (Ketteler and Seed, 2008) andwas used for
transfection, as well as GFP-LC3 plasmid, which was generously
donated by Dr. Tamotsu Yoshimori (Kabeya et al., 2000). Cells grown
to 70% conﬂuency were transfected with indicated plasmids using
Lipofectamine 2000 (Invitrogen, 11668-019), according to the
manufacturer's protocol. For the luciferase assay and the GFP-LC3puncta assay, cells were seeded at a density of 1.5×105 cells in 12-
well tissue culture plates.
Adenoviral vectors
AdCMV-lacZ (AdlacZ) has E1 deletion and has the lacZ gene as a
reporter. Adhz60 is an Ad vector with deletion of E1b gene (Rao et al.,
2004). Ad5 (Adwt) was obtained from ATCC and does not have any
deletions. Cells were infected with wt Ad5, Adhz60 (at an MOI of 4) or
AdlacZ (at an MOI of 10) in FBS-free medium for 1 h. Infected cells
were then untreated or treated with 3MA at 10 mM or rapamycin at
50 nM.We used a higher MOI of AdlacZ for compensation of its lack of
replication ability. The autophagy results are the same when AdlacZ
was used at MOIs of 4, 10, or 20. The cultures were collected at
indicated time points. Ad titers were determined as follow: cells went
through three cycles of freezing and thawing to release viruses from
the cells. Lysates were serially diluted to determine the titers in HEK-
293 cells by standard infective unit (IFU) measurement.
Gaussia luciferase assay
After transfection with the pEAK12-Actin-LC3-dNGLUC, superna-
tant samples were collected at indicated time points. GLUC activity
was determined using the Renilla Luciferase kit (Promega, E2810). To
avoid harvesting luciferase activity from detached cells, supernatants
were spun at 14,000 rpm for 5 min. Ten microliters of supernatant
was diluted (1:10) in 100 μl 1× renilla lysis buffer. Twenty microliters
of this mixture was added to 100 μl of renilla substrate prior to
analysis in a luminescence plate reader.
GFP-LC3 puncta
Plasmid vector containing green ﬂuorescent protein (GFP) linked
to microtubule-associated protein 1 light chain 3 (LC3) (pGFP-LC3)
was used to detect autophagosome formation in A549 cells caused by
Ad5 or Adhz60. After infection with Ad5 or Adhz60, no infected or Ad-
infected cells were cultured in the presence or absence of 3MA
(10 mM) or rapamycin (50 nM). 36 h later, cells were ﬁxed with 4%
formaldehyde and then observed under a ﬂuorescence microscope.
Cells were classiﬁed as having a predominantly diffuse GFP stain or
having numerous punctate structures representing autophagosomes.
Images were taken with Kodak MDS 290 software with the 40×
objective. The percentage of cells with GFP punctuate pattern was
calculated as punctuate GFP cell per total GFP cell percentage.
Western blot analysis
After respective treatment, the cells were harvested and lysed in a
radio immunoprecipitation assay (RIPA) buffer. Cell lysates were
centrifuged, and protein concentration was determined by BIO-RAD
DC protein assay (BIO-RAD, Hercules, CA). Equal amounts (50 ug) of
total protein were subjected to sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE) and electrotransferred to
Hybond-Polyvinylidene Diﬂuoride (PVDF) membranes (Amersham,
Arlington Heights, IL). The membranes were blocked with 5% dry milk
in Tris-buffered saline–Tween 20 (TBST), probed with the following
primary antibodies: rabbit polyclonal anti-LC3 (Novus Biologicals,
NB100-2331); rabbit polyclonal anti-Atg5 (C-terminal) (Sigma-
Aldrich, A0713); rabbit- antihuman Ad proteins virion (abcam,
ab6982); and rabbit-antihuman-α-actin pAb to ensure equal loading
of proteins. Next, the membranes were incubated with anti-mouse
immunoglobulin (Ig) or anti-rabbit Ig, peroxidase-linked, species-
speciﬁc whole antibody (Amersham, Piscataway, NJ). Chemilumines-
cent detection was performed with ECL reagents, according to the
manufacturer's instructions (Amersham).
15H. Rodriguez-Rocha et al. / Virology 416 (2011) 9–15MTT assay
Cell proliferation was assessed at three days after respective
treatments bymeasuring the conversion of the tetrazolium salt (MTT)
to formazan, according to themanufacturer's instructions (Boehringer
Mannheim, Indianapolis, IN). The supernatant from each plate was
collected for measurement of absorbance at a wavelength of 570 nm.
The results were expressed as the percentage of live cells.
Statistical analysis
The results of the in vitro assays were analyzed with the Student t-
test for unpaired data using a one-way ordinary parametric analysis of
variance. Pb0.05 was considered statistically signiﬁcant.
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